Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Internal Medicine

Resistant hypertension: diagnosis, evaluation, and the 2026 ACC stepwise treatment framework

Healthcare professional checks senior's blood pressure at clinic for health assessment.

Resistant hypertension — defined as blood pressure remaining above goal despite the use of three or more antihypertensive medications at optimal doses, including a diuretic — affects an estimated 10–15% of patients being treated for hypertension. Despite significant advances in pharmacotherapy, resistant hypertension continues to be associated with substantially elevated risks of cardiovascular events, stroke, heart failure, and chronic kidney disease. The 2026 ACC Expert Consensus Decision Pathway provides the most up-to-date framework for diagnosis, evaluation, and stepwise treatment of this challenging condition.

Defining resistant hypertension

The 2026 ACC Expert Consensus Decision Pathway defines resistant hypertension as blood pressure of 130/80 mmHg or higher despite maximally tolerated therapy from at least three complementary antihypertensive drug classes, one of which should be a diuretic. A critical first step is distinguishing true resistant hypertension from “pseudoresistance” — a common pitfall that leads to unnecessary treatment escalation.

Pseudoresistance encompasses several modifiable or reversible causes: white coat hypertension (elevated readings in a clinical setting but normal outside), medication nonadherence (the most common cause in clinical practice), suboptimal therapy (inappropriate drug combinations, inadequate doses, or use of short-acting agents), drug or substance interference (NSAIDs, oral contraceptives, decongestants, stimulants, excessive alcohol, and licorice are common culprits), and secondary causes of hypertension. Only after excluding all of these can a diagnosis of true resistant hypertension be established.

Out-of-office blood pressure measurement

The 2026 ACC pathway emphasizes that out-of-office blood pressure measurement is essential for confirming resistant hypertension. Office readings alone can be misleading due to white coat effect. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) is the gold standard, as it also identifies nocturnal hypertension (non-dipping pattern) — an independent cardiovascular risk factor common in resistant hypertension. When ABPM is unavailable, validated home blood pressure monitoring with proper technique using a calibrated device is an acceptable alternative.

Clinicians should also assess for masked hypertension — normal office readings but elevated ambulatory values — which can delay appropriate treatment intensification. Standardizing office blood pressure measurement using automated or validated techniques, with the patient seated quietly for five minutes without an observer present, reduces measurement variability and improves diagnostic accuracy.

Secondary causes of hypertension: systematic evaluation

Before labeling any patient with true resistant hypertension, an evaluation for secondary causes is essential. The most common secondary causes include:

  • Primary aldosteronism: The most common surgically correctable cause, present in 5–15% of resistant hypertension cases. Screening with plasma aldosterone-to-renin ratio is recommended.
  • Obstructive sleep apnea (OSA): Highly prevalent in resistant hypertension; nocturnal hypoxia activates the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS). CPAP therapy can lower blood pressure, though the magnitude of benefit varies.
  • Renal artery stenosis: Atherosclerotic or fibromuscular dysplasia-related stenosis impairs renal perfusion and activates RAAS. Duplex ultrasonography or CT/MR angiography may be warranted in suspected cases.
  • Chronic kidney disease: Volume overload and sympathetic activation contribute to resistant hypertension; eGFR should be routinely assessed.
  • Pheochromocytoma/paraganglioma: Rare but important; screen with plasma or urine metanephrines in patients with episodic hypertension, headache, diaphoresis, or palpitations.
  • Thyroid and other endocrine disorders: Hypothyroidism, hyperthyroidism, Cushing syndrome, and hyperparathyroidism can all contribute to hypertension.

Lifestyle interventions: the foundation of treatment

The 2026 ACC consensus strongly emphasizes that lifestyle interventions are active treatment strategies — not background advice to be mentioned and dismissed. Key recommendations include:

  • Sodium restriction: Target intake below 1,500 mg/day (or at minimum a 1,000 mg/day reduction); can lower blood pressure by 5–10 mmHg in hypertensive patients
  • Dietary patterns: DASH (Dietary Approaches to Stop Hypertension) or Mediterranean diet; associated with 8–14 mmHg reduction
  • Weight management: Each 5 kg of weight loss is associated with approximately 2–3 mmHg blood pressure reduction
  • Physical activity: At least 150 minutes of moderate-intensity aerobic activity weekly; combined aerobic and resistance training is preferred
  • Alcohol reduction: Target less than one standard drink per day for women and less than two for men
  • Potassium optimization: Increase dietary potassium (fruits, vegetables, legumes) unless contraindicated by CKD; counteracts sodium’s hypertensive effect

Optimizing pharmacotherapy: the stepwise approach

The cornerstone three-drug regimen for hypertension consists of a renin-angiotensin-aldosterone system (RAAS) blocker (ACE inhibitor or ARB), a calcium channel blocker (CCB), and a thiazide-type or thiazide-like diuretic. When patients remain uncontrolled on this combination, the 2026 ACC pathway recommends the following optimization before considering advanced therapies:

  • Switch from hydrochlorothiazide to longer-acting, more potent thiazide-like diuretics (chlorthalidone or indapamide), which provide more sustained 24-hour blood pressure lowering
  • Use long-acting CCBs (amlodipine preferred) and maximally tolerated RAAS blocker doses
  • Simplify dosing with combination pills to improve adherence
  • Address volume excess through optimized diuretic therapy; consider sequential nephron blockade with loop diuretics in patients with volume overload or reduced eGFR

The fourth-line agent of choice for true resistant hypertension is a mineralocorticoid receptor antagonist (MRA). Spironolactone has the most robust evidence in this setting, with the PATHWAY-2 trial demonstrating its superiority over other fourth-line agents (bisoprolol, doxazosin). For men who experience gynecomastia or sexual dysfunction with spironolactone, eplerenone is a selective MRA alternative with fewer androgenic side effects. Monitoring of potassium and creatinine is essential when adding MRAs, particularly in patients with CKD.

Advanced pharmacological options: aprocitentan and baxdrostat

The 2026 ACC pathway introduces two newer pharmacological options for confirmed true resistant hypertension after failure of an optimized four-drug regimen including an MRA:

Aprocitentan is a dual endothelin receptor antagonist (ETA/ETB blocker) approved by the FDA in 2024 for resistant hypertension. The PRECISION trial demonstrated that aprocitentan 12.5 mg reduced ambulatory systolic blood pressure by an additional 15.3 mmHg compared to placebo after 4 weeks, in patients already on a median of four antihypertensive drugs. Fluid retention and peripheral edema are the most common adverse effects, requiring vigilance — particularly in patients with reduced kidney function. Its use requires specialty input and careful patient selection.

Baxdrostat is a selective aldosterone synthase inhibitor (CYP11B2 inhibitor) in late-stage development. By reducing aldosterone synthesis with high selectivity over cortisol, it offers a more targeted approach than MRAs. Phase 2 data (BrigHTN trial) showed reductions of approximately 20 mmHg systolic blood pressure in patients with resistant hypertension. Regulatory submissions are anticipated in the near term. The 2026 ACC pathway designates it as an option for confirmed resistant hypertension after specialty consultation.

Device-based therapies: renal denervation

Renal sympathetic denervation (RDN) uses catheter-based ultrasound or radiofrequency energy to disrupt sympathetic nerve fibers in the renal arterial wall, reducing central sympathetic activation and blood pressure. The sham-controlled RADIANCE-HTN TRIO and SPYRAL HTN-ON MED trials demonstrated consistent blood pressure reductions in patients on background therapy.

The 2026 ACC pathway designates renal denervation as an option for carefully selected patients with confirmed true resistant stage 2 hypertension (systolic BP ≥160 mmHg) despite optimal medical therapy, or those unable to tolerate further medication intensification. Specialist referral to a hypertension or interventional cardiology center is essential before considering device therapy. Patient selection criteria include confirmed medication adherence, exclusion of secondary causes, and documentation of persistently elevated ambulatory readings.

Carotid baroreceptor amplification (baroreflex activation therapy) with an implantable device represents another device-based option. By electrically stimulating the carotid sinus, it activates baroreceptors that inhibit sympathetic outflow. It may be considered when other options have failed and in specialist centers with appropriate expertise.

Addressing social and systemic barriers

The 2026 ACC pathway explicitly incorporates strategies for addressing social determinants of health that affect blood pressure management. Food insecurity, limited access to fresh produce, housing instability, occupational stress, and health literacy all contribute to medication nonadherence and lifestyle barriers. Clinicians are encouraged to screen for these barriers using validated tools and to coordinate with social work, pharmacy, and community health resources. Simplified medication regimens, single-pill combinations, and 90-day prescription supplies improve adherence in vulnerable populations.

Multidisciplinary team approach and specialist referral

The complexity of resistant hypertension often requires multidisciplinary input. The 2026 pathway recommends specialist referral — to hypertension specialists, nephrologists, or cardiologists — for patients with confirmed true resistant hypertension, suspected secondary causes, consideration of advanced pharmacological or device-based therapies, or complex comorbidities including CKD stage 4–5, heart failure, or multimorbidity. Nurse practitioners, clinical pharmacists, and dietitians can play important supporting roles in patient education, medication management, and dietary counseling.

Conclusion

Resistant hypertension represents a clinically important and high-risk condition requiring a systematic, stepwise approach. The 2026 ACC Expert Consensus Decision Pathway provides practical guidance for confirming the diagnosis, excluding pseudoresistance and secondary causes, optimizing lifestyle and pharmacotherapy, and appropriately escalating to advanced treatments including aprocitentan, baxdrostat, and renal denervation in selected patients. Accurate blood pressure measurement, medication adherence support, and multidisciplinary care coordination are the foundations of successful management. As newer pharmacological and device-based options continue to emerge, the therapeutic landscape for resistant hypertension is becoming increasingly comprehensive.

© Medsenna. Quoting a short excerpt with a link to this page is welcome; republishing the full article requires our written permission.

Keep reading